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 Knowledge of peritoneal anatomy and 
physiology is constantly being applied to 
how we prescribe and perform peritoneal 
dialysis (PD). Also important is the gen-
eral comprehension of how we implement 
this therapy. Mehrotra and colleagues 1 
(this issue) utilized the United States Renal 
Data System (USRDS) to describe how 
American nephrologists practice PD. 
Using the years 1996 – 1998 as a reference, 
they compared changes in PD practice in 
1999 – 2001 and 2002 – 2004.  eir 3 ndings 
regarding the cornucopia of material in 
the data set are just the tip of the iceberg. 
Quite probably, many more papers are in 
preparation from the present analyses, 
generously shared with us now to whet 
our appetite. 
 The theme of the work of Mehrotra 
 et al. 1 is the comparison of outcomes 
utilizing continuous ambulatory PD 
(CAPD) versus automated PD (APD). In 
short, outcomes were similar.  e initial 
question of CAPD versus APD outcomes 
arose because overall outcomes of PD 
improved, and simultaneously, the preva-
lence of APD rose over that of CAPD.  e 
authors sought to de3 ne or refute a cause 
and eE ect. What the authors have not dis-
cussed yet are the other practice variables 
that aE ect the utilization of CAPD versus 
APD in the United States. A drill down on 
the data may yield that fruit. 
 APD is slightly more expensive than 
CAPD, for several reasons. First, the cycler 
has to be purchased or leased. Second, in 
general, greater solution volumes are 
needed, albeit in larger, more cost-e  cient 
bags.  ird, cycler training plus manual 
training for APD takes longer than mere 
manual exchange training for CAPD. 
Lastly, the more expensive icodextrin 
solution is more likely to be used in APD 
for the long dwell than it is in CAPD ’ s long 
dwell. So if APD is more expensive than 
CAPD, why is it becoming more preva-
lent?  ere is more training revenue to the 
dialysis facility with the extended training 
required for APD.  is revenue exceeds 
that of monthly supervision fees. How-
ever, I do not think this is the driver of the 
popularity of APD. In my opinion, the 
answer is simple and, quite frankly, refutes 
the attacks on for-profit large dialysis 
organizations. Patients prefer it, and pro-
viders accommodate patient preferences 
at the potential expense of pro3 t margins 
(lost because of the use of more 1 uids). 
 At the start of the observation period of 
Mehrotra  et al. 1 (1996 – 1998), most 
 American PD programs were training 
patients for just CAPD.  en, toward the 
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 Learning about the practice 
of peritoneal dialysis 
 Thomas A.  Golper 1 
 Observational studies are valuable  and provocative. We are learning 
about how we practice peritoneal dialysis (PD) and how we might 
improve on that practice. For example, outcomes of PD  therapy are not 
worse in large patients. Perhaps this will encourage physicians and 
patients to utilize PD in large patients. In addition, better descriptions of 
how we practice will help to identify systematic barriers to the 
advancement of home dialysis. 
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 completion of training or, far more likely, 
several months later, patients were 
retrained for APD. At that time, the peri-
toneal equilibration test and comparable 
peritoneal transport assessment tests were 
just being routinely administered, and 
these transport-status tests were rarely the 
determining factor in deciding between 
CAPD and APD. As we went forward and 
became more familiar with how to use 
peritoneal equilibration test data, and as 
transport status and behavior became bet-
ter understood, more patients in higher 
transport-status categories were urged to 
consider APD.  us, APD grew as a result 
of patient preference related to lifestyle, as 
well as in response to the emphasis to 
direct higher transporters toward APD. 
So while Mehrotra  et al. 1 considered the 
role of ascertainment bias in their results, 
I think the movement of higher transport-
ers to APD was secondary to the major 
determinant — lifestyle preferences. A fol-
low-up study could explore when the 3 rst 
peritoneal equilibration test was per-
formed relative to the decision to use APD 
rather than CAPD. Unfortunately, data 
such as these are sometimes not in the 
USRDS database. 
 Another area touched on by Mehrotra 
 et al. 1 is the outcome relative to the size 
(translate as  ‘ experience ’ ) of the PD pro-
gram.  e authors could demonstrate an 
improvement in technique survival only 
with larger programs. I was critical of the 
way these data were analyzed and urge 
further study of the same data set. I have 
expressed that to the authors. If outcomes 
other than just technique survival are 
superior in larger programs, then, in my 
opinion, this supports the consolidation 
of programs to take advantage of the ben-
e3 ts of experience. In Canada, Europe, 
Asia, and elsewhere, PD programs are 
much larger in patient census than are 
typical American programs. Mehrotra 
himself, with other colleagues, has 
described the problems inherent in small 
PD programs, especially in training 
young nephrologists. 2 Consolidation of 
several smaller programs into a larger 
program was done in Phoenix, Arizona, 
with positive eE ects. So if larger programs 
produce better results and consolidation 
is achievable, there may be momentum to 
consolidate. Competition seems a likely 
barrier to this at present, but large dialysis 
organizations could assist in an initiative 
to consolidate several small PD programs 
within their organization in a convenient 
geographic area. 
 Yet another area mentioned by Mehrotra 
 et al. 1 is the  ‘ protective ’ eE ect of larger body 
mass index, a concept I call the  ‘ Godzilla 
effect ’ (size does matter). Because the 
paper ’ s focus is on CAPD versus APD, this 
topic is not discussed in any detail. In 
hemodialysis patients, larger body mass 
index is clearly a survival advantage in 
observational studies, 3 – 5 whereas in PD 
patients, the argument is unresolved, with 
con1 icting observations. 3,6,7  e analysis 
of Mehrotra  et al. 1 updates the previous 
USRDS data with what appears to be the 
largest data set examined to date. Patients 
with a larger body mass index require more 
dialysis to achieve the same level of solute 
removal when normalized to size.  at 
leads to more 1 uids (and expense), more 
exchanges (and peritonitis risk), and per-
haps a dissuasion from even attempting 
PD.  e 3 ndings that larger PD patients 
have a survival advantage over smaller 
patients may encourage the use of PD in 
larger patients previously precluded from 
the therapy. Whenever dialysis patient out-
come and body size are considered, it raises 
a major unanswered question: What is the 
best normalizing factor in measuring the 
dose of delivered dialysis? 8 Could we use 
this data set to address this? 
 Mehrotra  et al. 1 show that outcomes 
have improved over the 9-year observa-
tion period.  e (US) National Kidney 
Foundation ’ s original Dialysis Outcomes 
Quality Initiative (DOQI), formed in 
1995, published peritoneal dialysis 
adequacy guidelines in 1997 and updated 
them in 2000, and again in 2006. Although 
mentioned only in passing by Mehrotra
 et al. , 1 it seems likely that these DOQI 
guidelines in1 uenced the practice of PD 
in the United States and may be part of 
the explanation for the improvement 
noted by Mehrotra  et al. 1 First, if DOQI 
PD adequacy guidelines had discouraged 
physicians from oE ering PD to patients 
considered marginal, then outcomes 
might have improved merely because of a 
selection bias.  is would be considered 
an unintended consequence of the guide-
lines. An intended consequence would be 
that the guidelines were, in fact, utilized 
and educated physicians, dialysis staE , 
patients, and payers, leading to an 
improved practice of PD. Both explana-
tions are quite plausible. 
 Over the time course of the study by 
Mehrotra  et al. , 1 patients initiated dialysis 
at progressively higher estimated glomeru-
lar 3 ltration rates (USRDS 2004 Annual 
Data Report, Figures 3.28 and 3.29 9 ). Is 
this lead-time bias the explanation for the 
improved outcomes? 10 I personally think 
not, as the earlier initiation at higher 
glomerular 3 ltration rates re1 ects comor-
bidities and the hope that starting dialysis 
will salvage patients who are ill from their 
comorbidities, not uremia (USRDS 2003 
Annual Data Report, Figure 3.27; 11 USRDS 
2004 Annual Data Report, Table 3b 9 ).  is 
question of  earlier initiation of dialysis 
 Table 1  |  Systematic barriers to home 
dialysis in the United States 
 Governmental / Medicare 
  Centers for Medicare and Medicaid 
Services requirements for visits and 
reimbursements 
  Reimbursement strategies favoring graft 
placement instead of L stulae 
  Lack of home-care partner support 
  Delays in accreditation and certiL cation 
of new units 
 
 Educational issues 
  Inadequate patient education about 
home therapies 
  Inadequate physician education / training /
 experience in home dialysis 
  Inadequate dialysis-staM  education /
 training / experience in home dialysis 
 
 Attitude / philosophy of large dialysis 
organizations 
  Availability of state-of-the-art equipment 
and solutions 
  Delivery of products / supplies 
  Pharmacy preparations readily available  
  Business conN icts trumping patient care 
  Failure of laboratory services to accom-
modate home dialysis needs 
  Use of data for commercial advantage 
rather than for practical improvements 
  Treatment of home dialysis clinic as an 
addendum to in-center hemodialysis, 
especially regarding physical environment 
and staO  ng 
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will be addressed later this year with the 
 analysis and report of the Initiating 
 Dialysis Early and Late (IDEAL) trial. 12 
 Home dialysis is at a crossroads in the 
United States.  e incident dialysis popu-
lation is older and carries more comor-
bidities than ever in the history of the 
End-Stage Renal Disease Program. Such 
a patient population is unlikely to seek 
self-care dialysis at home. On the other 
hand, the shortage of dialysis nurses and 
the prevalence of infections with in-
center dialysis units are stimuli to send 
patients home. Yet there are many sys-
tematic barriers to the advancement of 
home dialysis. A brief list of these is 
shown in  Table 1 .  e North American 
chapter of the International Society for 
Peritoneal Dialysis is spearheading an 
initiative to publicize these barriers such 
that all stakeholders can participate in 
overcoming them and, by doing so, 
advance the utilization of all home 
 dialysis therapies. 
 So observations that describe how we 
practice can be exceedingly useful and 
provocative. We must continue to encour-
age such investigations, including a more 
in-depth analysis of the current Mehrotra 
 et al. data set. 1 
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